Program
Please note that this meeting will take place as an in-person event in San Diego, California and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
FRIDAY, MARCH 7
SATURDAY, MARCH 8
- Plenary Session 1 : Cellular Therapies in ALL
- Plenary Session 2: B-ALL Biology
- Plenary Session 3: Molecularly Targeted Therapies in ALL
- Plenary Session 4: T-ALL Biology
- Plenary Session 5: (Hematologic Malignancies Working Group Session)
Sunday, March 9
- Plenary Session 6: Targeted Immunotherapies in Frontline Therapies in ALL
- Plenary Session 7 : Diagnostics and Prognostics in ALL
- Plenary Session 8: Future Direction in ALL Therapy
- Closing Remarks
REGISTRATION
4-8 p.m.
WELCOME AND Keynote Lectures
6-7 p.m.
Opening Reception
7:15-9:30 p.m.
Continental Breakfast
7-8 a.m.
Plenary Session 1: Cellular therapies in ALL
8-9:35 a.m.
- Nirali Shah, National Institute of Health, Bethesda, Maryland
- Rayne Rouce, Texas Children’s, Houston, Texas
- Lori Muffly, Stanford University, Stanford, California
Break
9:35-9:50 a.m.
Plenary Session 2: B-ALL Biology
9:40-11:25 a.m.
- Caner Saygin, University of Chicago, Chicago, Illinois
- Matt Witkowski, University of Colorado, Aurora, Colorado
- Kara Davis, Stanford University, Stanford, California
Break
11:25-11:40 a.m.
Plenary Session 3 : Molecularly targeted therapies in ALL
11:40 a.m.-1:15 p.m.
- Cristina Papayannidis, University of Bologna, Bologna, Italy
- Wendy Stock, University of Chicago, Chicago, Illinois
Free time / Lunch on Own
1:15-2:45 p.m.
Plenary Session 4: T-ALL Biology
2:45-4:20 p.m.
- Charles Mullighan, St. Jude’s Children’s Hospital, Memphis, Tennessee
- Marc Mansour ,UCL, London
- Daniel Herranz, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Break
4:20-4:35 p.m.
Plenary Session 5: (Hematologic Malignancies Working Group Session)
4:35-6:05 p.m.
Spotlight on Proffered Papers Session
6:15-7 p.m.
Poster Session / Reception
7:15-9:15 p.m.
Continental Breakfast
7-8 a.m.
Plenary Session 6: Targeted Immunotherapies in frontline therapies in ALL
8-9:35 a.m.
- Sumit Gupta, Hospital for Sick Kids, Toronto, Ontario, Canada
Break
9:35-9:50 a.m.
Plenary Session 7 : Diagnostics and Prognostics in ALL
9:50-11:25 a.m.
- Aaron Logan, University of California San Francisco, San Francisco, California
- Jun Yang, St. Jude’s Children’s Hospital, Memphis, Tennessee
Break
11:25-11:40 a.m.
Plenary Session 8: Future direction in ALL therapy
11:40 a.m.-1: 15 p.m.
- Elizabeth Raetz, New York University, New York, New York
- Ibraham Aldoss, City of Hope, Irvine, California
- Dave Teachey, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Closing Remarks
1:15-1:30 p.m.